Screen Shot 2019-06-06 at 11

Understanding NAFLD Referral Pathways in the UK and Ireland

Gilead Sciences Ltd commissioned PHAST to undertake some research to inform the next steps in NASH and NAFLD Service Delivery. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, they seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases and cardiovascular conditions.

Phase 1:  Desktop exercise of evidence synthesis and data analysis

Phase 2:  Stakeholder mapping, engagement and consultation

Phase 3:  Recommendations for supporting the future development of NAFLD/NASH care pathways

You can download the presentation below


For more information about our work or if you would like to speak to a member of the PHAST Team contact us.

Sign up for PHAST News & Views